Navigation Links
In Relapsed/Refractory Multiple Myeloma, Thought Leaders Are Optimistic that the Combination of Carfilzomib, Lenalidomide and Dexamethasone Will Be the Most Efficacious Regimen
Date:5/14/2013

BURLINGTON, Mass., May 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European hematological oncologists indicate that overall survival is the factor that most influences their prescribing decisions for relapsed/refractory multiple myeloma, and that increased overall survival is associated with the highest level of unmet need. Interviewed thought leaders are optimistic that the CRd regimen— carfilzomib (Onyx Pharmaceuticals/Ono Pharmaceutical's Kyprolis) in combination with lenalidomide (Celgene's Revlimid) and dexamethasone—will show advantages over sales-leading lenalidomide plus dexamethasone (the Rd regimen) on this attribute in the ongoing Phase III ASPIRE trial.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled As Carfilzomib and Pomalidomide Make Inroads Into the Market, What Key Attributes Will Differentiate Emerging Therapies According to Hematological Oncologists and Payers? finds that surveyed U.S. managed care organization (MCO) pharmacy directors demand that emerging therapies provide significant improvements in overall survival over Rd—a premium-priced standard-of-care regimen for relapsed/refractory multiple myeloma—to justify their cost and secure reimbursement. Notably, half of surveyed payers would not reimburse a new therapy priced the same as Rd or higher that offers a three-month improvement in overall survival over Rd, citing insufficient overall clinical benefit as one of the key reasons for not granting reimbursement.

The report also finds that surveyed U.S. and European hematological oncologists identified neurotoxicity as the safety and tolerability attribute that is most important to prescribing decisions in relapsed/refractory multiple myeloma, thus indicating the persisting high level of unmet need for therapies with a more favorable peripheral neuropathy profile.

"Despite the improvements effected by carfilzomib and the subcutaneous formulation of bortezomib (Takeda/Janssen-Cilag/Janssen's Velcade) on the incidence of peripheral neuropathy associated with standard intravenous bortezomib, our survey results suggest that further improvement in neurotoxicity remains a key opportunity for product differentiation," said Decision Resources Senior Business Insights Analyst Khurram Nawaz , M.Sc. "Early-stage clinical data suggest that the oral proteasome inhibitor MLN9708 (Takeda/Millennium) is associated with little peripheral neuropathy. MLN9708 has the potential to gain a competitive edge over currently available proteasome inhibitors if it can replicate these promising results in its ongoing Phase III trial, provided it is at least as efficacious as bortezomib and carfilzomib."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. Hobart Group Holdings Marks 10th Anniversary With Multiple Milestones
4. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
5. For Pharma Companies, Launching Multiple Similar Products Can Be a "Good Problem" but Requires Smart Resourcing
6. Deploying an Effective Pay for Performance Bonus System that Works Across Multiple Industry Sectors
7. Aurigene Announces Transition of Multiple Programs to Clinical Development in its Collaboration Business
8. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
9. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
10. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
11. MedNet Solutions To Participate In Multiple Clinical Research Conferences In April 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today ... Inc.,s Supplier Horizon Award . One ... Guerbet was recognized for its support of Premier members ... through clinical excellence, and commitment to lower costs. ... receive this recognition of our outstanding customer service from ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
Breaking Medicine News(10 mins):